Allogene Therapeutics, Inc.

Hello, and thank you for standing by. Welcome to Allogene Therapeutics' third quarter 2025 conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.

Thank you, Operator, and welcome everyone to Allogene's third quarter 2025 conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the third quarter of 2025. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session. We recognize that historically questions have been multifaceted, but note that we will endeavor to keep this call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer, Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer, and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, and financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of the potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allergen disclaims any obligation to update these statements. I'll now turn the call over to David.

Thank you, Christine. This quarter has been about conviction, conviction in our science, in the path we have chosen, and in the future we are building for patients. We are aware of the shifting conversation in the field. Every new modality brings excitement, and speculation about what the future might hold. But true innovation isn't about chasing what's next. It is about delivering what patients need now. And if a platform can safely, effectively, and at scale deliver curative therapies, it doesn't just shape the future. It redefines it. At Allergen, our focus has never wavered. We are advancing the platform we believe is not only essential to making cell therapies accessible and scalable, but one that could fundamentally upend the current paradigm and even the one others are still imagining by making the promise of curative one-time off-the-shelf cell therapy a reality today. And that's exactly what allogeneic cell therapy represents. It's not a breach to something else. It is the foundation. Allogeneic technology delivers the scalable backboard needed to democratize access, reduce the overall cost of care, and bring transformative and potentially curative treatment to far more patients than ever before. We expect allogeneic therapy to be central across oncology and autoimmune disease because it combines the precision and power of autologous with a flexible, efficient, and commercially viable model no other approach can. Its capacity for multiplex gene engineering allows the creation of future platform products within a single cell, an advance that we believe will be critical for addressing complex cancers including thalassemers. This isn't incremental progress. It's a leap forward that reshapes what's possible. We have done the hard work to make the future real. Our leadership in manufacturing, translational science, and clinical development positions allergens to endure and lead, setting the standard for how cell therapy can be delivered at scale and with impact. Each of our programs, Semicell, Allo329, and Allo316, reflects that strategy to make cell therapy scalable, practical, accessible, and in some cases, curative. At Allogene, we are not waiting for the future of cell therapy. We are creating it with conviction, with data, and with a platform built for lasting impact. As we move into next year, we are preparing for what we expect to be a defining moment with pivotal interim data from CEMETCELL in the Alpha 3 trial in first-line consolidation and proof of concept from ALO3 to 9 in autoimmune disease. Both milestones that we believe will shape the next era of cell therapy. With that, I will now turn it to Zach to share updates on our R&D progress.